Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Olea europaea pollen polymerized extract
- Development stage
- Phase 3
- Lead developer
- Inmunotek
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Olea europaea pollen polymerized extract is a glutaraldehyde-modified allergen immunotherapy (allergoid) derived from olive tree (Olea europaea) pollen. Developed by Inmunotek and ROXALL Medizin, it is designed for subcutaneous immunotherapy (SCIT) to treat moderate-to-severe allergic rhinitis, allergic rhinoconjunctivitis, and asthma induced by olive pollen sensitization. Chemical polymerization of the allergen extract with glutaraldehyde reduces its IgE-binding capacity (antigenicity) while preserving its immunogenicity, thereby enhancing safety and tolerability. This allows for accelerated up-dosing schedules and the administration of higher allergen doses to induce long-term immune tolerance.
- Brand names
- Allermune Polymerized Olea europaeaAlxoidClustekClustoidClustoid MaxCluxin
- Other names
- Olea europaea pollen allergoidglutaraldehyde-polymerized Olea europaea pollen extractglutaraldehyde-polymerized olive pollen extractolive pollen allergoidpolymerized Olea europaea pollen extractpolymerized olive pollen extract
02
Targets
sIgG4 (Allergen-specific immunoglobulin G4)TCR (T cell antigen receptor complex)
Beyond the preview
Go deeper on Olea europaea pollen polymerized extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Olea europaea pollen polymerized extract.